The first aims to treat Leber congenital amaurosis—a rare condition causing early childhood blindness—by local subretinal injection of an AAV-based CRISPR-Cas9 vector targeting a cryptic exon in the CEP290 gene (EDIT-101, NCT03872479).14 The gene discussed is CEP290; the disease is Blindness.